KAM
SUPN icon

Krensavage Asset Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Krensavage Asset Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.1M Hold
280,681
– – 4.96% 8
2026
Q1 		$14.5M Sell
280,681
-32,818
-10% -$1.67M 5.67% 7
2025
Q4 		$15.6M Sell
313,499
-49,980
-14% -$2.43M 5.5% 8
2025
Q3 		$17.4M Sell
363,479
-108,897
-23% -$4.39M 7.4% 6
2025
Q2 		$14.9M Buy
472,376
+40,390
+9% +$1.29M 7.88% 6
2025
Q1 		$14.1M Buy
+431,986
New +$15.3M 7.82% 4

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Krensavage Asset Management's SUPN Position: Q2 2026 in Review

Krensavage Asset Management held its Supernus Pharmaceuticals (SUPN) position steady in Q2 2026 at 280,681 shares worth $13.1M. The position accounts for 4.96% of the portfolio, ranked #8.

Krensavage Asset Management first reported a position in SUPN in Q1 2025 and has held it in 6 quarters since. The position peaked at $17.4M in Q3 2025. 334 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • Krensavage Asset Management held 280,681 shares of Supernus Pharmaceuticals worth $13.1M as of Q2 2026.
  • Krensavage Asset Management left its Supernus Pharmaceuticals share count unchanged in Q2 2026.
  • Supernus Pharmaceuticals made up 4.96% of Krensavage Asset Management's portfolio in Q2 2026, its #8 holding.
  • Krensavage Asset Management first reported a position in Supernus Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
  • Krensavage Asset Management's Supernus Pharmaceuticals position peaked at $17.4M in Q3 2025.
  • 334 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Krensavage Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.